PRF Technologies Ltd.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $3.0M
- Price
- $0.9971
- % Change (Daily % change from the live per-ticker quote feed.)
- -0.29%
- Volume
- 68.0K
About
PRF Technologies Ltd. operates as a specialized pharmaceutical company, currently in the clinical development stage, with a focus on pioneering treatments that deliver sustained post-surgical pain management. Central to its pipeline is PRF-110, a distinctive clear, viscous, oil-based solution. This innovative product is engineered for direct application into surgical incisions, aiming to provide targeted and prolonged alleviation of discomfort following operations. PRF-110 is presently undergoing assessment in two pivotal Phase 3 clinical trials, specifically for individuals recovering from bunionectomy and hernia repair procedures. The company, which was originally incorporated in 2007 under the name PainReform Ltd., maintains its headquarters in Tel Aviv, Israel.
Quick stats
Shares outstanding3.0M
Computed float840.3K
Float / shares27.6%
Key info
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001801834
Websitehttps://www.painreform.com
AI Summary
AI-generated1/9
standardbullishoperations update
PRF Technologies Issues Letter to Shareholders Highlighting Strengthened Financial Position and Building Momentum Across Its Biotechnology and AI-Driven Energy Platforms
PRF Technologies issued a shareholder letter detailing a $10 million raise through an equity line facility, which the company states has substantially strengthened its balance sheet and funded strategic flexibility.
On the biotechnology side, subsidiary LayerBio is advancing operational preparations for a Phase 2 clinical trial of OcuRing-K, while preclinical results for PRF-110 demonstrated 72-hour analgesic activity comparable to an approved benchmark.
The company's DeepSolar unit validated its Predict platform with European market data, added Battery-to-Revenue Intelligence, and joined the NVIDIA Connect program ahead of showcasing its GridFeed solution at an industry conference.
Red flags
- Equity line facility financing
- Forward-looking statements cite history of significant losses